Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Depreciation & Amortization (CF) (2018 - 2023)

Endonovo Therapeutics has reported Depreciation & Amortization (CF) over the past 12 years, most recently at $161728.0 for Q3 2023.

  • Quarterly results put Depreciation & Amortization (CF) at $161728.0 for Q3 2023, changed 0.0% from a year ago — trailing twelve months through Sep 2023 was $323456.0 (down 50.0% YoY), and the annual figure for FY2022 was $646912.0, changed 0.24%.
  • Depreciation & Amortization (CF) for Q3 2023 was $161728.0 at Endonovo Therapeutics, roughly flat from $161728.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for ENDV hit a ceiling of $163563.0 in Q3 2020 and a floor of $161699.0 in Q2 2020.
  • Median Depreciation & Amortization (CF) over the past 5 years was $161728.0 (2021), compared with a mean of $162276.1.
  • Biggest five-year swings in Depreciation & Amortization (CF): increased 0.57% in 2020 and later fell 1.12% in 2021.
  • Endonovo Therapeutics' Depreciation & Amortization (CF) stood at $162631.0 in 2019, then changed by 0.0% to $162631.0 in 2020, then decreased by 0.56% to $161728.0 in 2021, then changed by 0.0% to $161728.0 in 2022, then changed by 0.0% to $161728.0 in 2023.
  • The last three reported values for Depreciation & Amortization (CF) were $161728.0 (Q3 2023), $161728.0 (Q4 2022), and $161728.0 (Q3 2022) per Business Quant data.